- Home
- AMLX vs RLAY Comparison
AMLX vs RLAY Comparison
Compare AMLX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- RLAY
- Stock Information
- Founded
- AMLX 2014
- RLAY 2015
- Country
- AMLX United States
- RLAY United States
- Employees
- AMLX N/A
- RLAY N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMLX Health Care
- RLAY Health Care
- Exchange
- AMLX Nasdaq
- RLAY Nasdaq
- Market Cap
- AMLX 749.9M
- RLAY 610.3M
- IPO Year
- AMLX 2022
- RLAY 2020
- Fundamental
- Price
- AMLX $8.00
- RLAY $3.54
- Analyst Decision
- AMLX Strong Buy
- RLAY Strong Buy
- Analyst Count
- AMLX 7
- RLAY 12
- Target Price
- AMLX $12.00
- RLAY $18.45
- AVG Volume (30 Days)
- AMLX 1.0M
- RLAY 2.8M
- Earning Date
- AMLX 08-07-2025
- RLAY 08-07-2025
- Dividend Yield
- AMLX N/A
- RLAY N/A
- EPS Growth
- AMLX N/A
- RLAY N/A
- EPS
- AMLX N/A
- RLAY N/A
- Revenue
- AMLX N/A
- RLAY $8,355,000.00
- Revenue This Year
- AMLX N/A
- RLAY $17.59
- Revenue Next Year
- AMLX N/A
- RLAY N/A
- P/E Ratio
- AMLX N/A
- RLAY N/A
- Revenue Growth
- AMLX N/A
- RLAY N/A
- 52 Week Low
- AMLX $2.05
- RLAY $1.78
- 52 Week High
- AMLX $8.72
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- AMLX 53.91
- RLAY 52.25
- Support Level
- AMLX $7.48
- RLAY $3.31
- Resistance Level
- AMLX $8.49
- RLAY $3.61
- Average True Range (ATR)
- AMLX 0.40
- RLAY 0.21
- MACD
- AMLX -0.06
- RLAY -0.02
- Stochastic Oscillator
- AMLX 51.49
- RLAY 68.67
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).